{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:00:58Z","timestamp":1788490858969,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The presence of significant liver inflammation is an important indication for antiviral therapy in immune-tolerant (IT)phase with chronic hepatitis B(CHB) patients. This study aims to establish a non-invasive model to assess significant liver inflammation in the IT-phase of CHB patients. This multicenter retrospective study included a total of 535 IT-phase CHB patients who underwent liver biopsy, and were randomly divided into a training and a validation set. In the training cohort, the relevant indices were initially screened using univariate analysis. Then the least absolute shrinkage and selection operator and multivariable logistic regression were used to identify the significant independent risk factors and establish a predictive model. A diagnostic nomogram was constructed. Calibration curves, decision curve analysis, and receiver operating characteristic curves were utilized to evaluate the performance of the nomogram. In this study, 37.0% of the patients exhibited significant liver inflammation. Baseline characteristics revealed a median age of 35.0 years, with males accounting for 51.7% of the cohort. Age, Aspartate aminotransferase (AST), Prothrombin (PT), Albumin (ALB) and Hepatitis B virus DNA (HBV DNA) were identified as independent predictors of significant liver inflammation in the immune-tolerant phase, and a nomogram was constructed based on these indicators. The predictive model demonstrated good calibration and discrimination in both the training set and the validation set (aera under the curve (AUC) of 0.741 and 0.740, respectively). The nomogram can accurately identify significant liver inflammation in immune-tolerant phase CHB patients and facilitate the early initiation of antiviral therapy, thereby reducing the need for clinical liver biopsies.<\/jats:p>","DOI":"10.1038\/s41598-025-87756-4","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:18:57Z","timestamp":1737674337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Noninvasive diagnosis model for predicting significant liver inflammation in patients with chronic hepatitis B in the immune-tolerant phase"],"prefix":"10.1038","volume":"15","author":[{"given":"Shanshan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangshan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"21","key":"87756_CR1","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1056\/NEJMra1810477","volume":"380","author":"DL Thomas","year":"2019","unstructured":"Thomas, D. L. Global elimination of Chronic Hepatitis. N Engl. J. Med. 380 (21), 2041\u20132050 (2019).","journal-title":"N Engl. J. Med."},{"issue":"6","key":"87756_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"Global prevalence","year":"2018","unstructured":"Global prevalence. Treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol. Hepatol. 3 (6), 383\u2013403 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"10159","key":"87756_CR3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman, K. J. et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 392 (10159), 2052\u20132090 (2018).","journal-title":"Lancet"},{"key":"87756_CR4","doi-asserted-by":"crossref","unstructured":"EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol, 2017. 67(2): pp. 370\u2013398. (2017).","DOI":"10.1016\/j.jhep.2017.03.021"},{"issue":"1","key":"87756_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63 (1), 261\u2013283 (2016).","journal-title":"Hepatology"},{"issue":"1","key":"87756_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin, S. K. et al. Asian-pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10 (1), 1\u201398 (2016).","journal-title":"Hepatol. Int."},{"issue":"1","key":"87756_CR7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijrobp.2019.04.032","volume":"105","author":"XD Huang","year":"2019","unstructured":"Huang, X. D. et al. Evolution and Dosimetric Analysis of Magnetic Resonance imaging-detected brain stem Injury after Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 105 (1), 124\u2013131 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"9","key":"87756_CR8","doi-asserted-by":"publisher","first-page":"e0203220","DOI":"10.1371\/journal.pone.0203220","volume":"13","author":"YF Xing","year":"2018","unstructured":"Xing, Y. F. et al. Clinical and histopathological features of chronic hepatitis B virus infected patients with high HBV-DNA viral load and normal alanine aminotransferase level: a multicentre-based study in China. PLoS One. 13 (9), e0203220 (2018).","journal-title":"PLoS One"},{"issue":"11","key":"87756_CR9","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1111\/jvh.13606","volume":"28","author":"J Shen","year":"2021","unstructured":"Shen, J. et al. Baseline HBV-DNA load plus AST\/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: a multicentre study. J. Viral Hepat. 28 (11), 1587\u20131596 (2021).","journal-title":"J. Viral Hepat."},{"key":"87756_CR10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12876-014-0218-6","volume":"14","author":"S Praneenararat","year":"2014","unstructured":"Praneenararat, S. et al. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication. BMC Gastroenterol. 14, 218 (2014).","journal-title":"BMC Gastroenterol."},{"issue":"4","key":"87756_CR11","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67 (4), 1560\u20131599 (2018).","journal-title":"Hepatology"},{"issue":"2","key":"87756_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12072-021-10153-2","volume":"15","author":"M Duan","year":"2021","unstructured":"Duan, M. et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol. Int. 15 (2), 318\u2013327 (2021).","journal-title":"Hepatol. Int."},{"issue":"4","key":"87756_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hep4.1859","volume":"6","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Presence of Liver inflammation in Asian patients with chronic Hepatitis B with Normal ALT and detectable HBV DNA in absence of liver fibrosis. Hepatol. Commun. 6 (4), 855\u2013866 (2022).","journal-title":"Hepatol. Commun."},{"issue":"6","key":"87756_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2010.05.035","volume":"53","author":"F Degos","year":"2010","unstructured":"Degos, F. et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J. Hepatol. 53 (6), 1013\u20131021 (2010).","journal-title":"J. Hepatol."},{"issue":"5","key":"87756_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/hepr.12385","volume":"45","author":"M Alboraie","year":"2015","unstructured":"Alboraie, M. et al. Value of egy-score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and Forns\u2019 index in chronic hepatitis C virus. Hepatol. Res. 45 (5), 560\u2013570 (2015).","journal-title":"Hepatol. Res."},{"issue":"1","key":"87756_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/hep.27382","volume":"61","author":"G Xiao","year":"2015","unstructured":"Xiao, G., Yang, J. & Yan, L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology 61 (1), 292\u2013302 (2015).","journal-title":"Hepatology"},{"issue":"8","key":"87756_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1097\/MCG.0000000000000250","volume":"49","author":"CL Lin","year":"2015","unstructured":"Lin, C. L. et al. Serum biomarkers predictive of significant fibrosis and cirrhosis in Chronic Hepatitis B. J. Clin. Gastroenterol. 49 (8), 705\u2013713 (2015).","journal-title":"J. Clin. Gastroenterol."},{"issue":"2","key":"87756_CR18","first-page":"507","volume":"45","author":"AS Lok","year":"2007","unstructured":"Lok, A. S. & McMahon, B. J. Chronic Hepat. B Hepatol., 45(2): 507\u2013539. (2007).","journal-title":"Chronic Hepat. B Hepatol."},{"issue":"3","key":"87756_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","volume":"13","author":"PJ Scheuer","year":"1991","unstructured":"Scheuer, P. J. Classification of chronic viral hepatitis: a need for reassessment. J. Hepatol. 13 (3), 372\u2013374 (1991).","journal-title":"J. Hepatol."},{"key":"87756_CR20","doi-asserted-by":"publisher","first-page":"688091","DOI":"10.3389\/fmed.2021.688091","volume":"8","author":"X Li","year":"2021","unstructured":"Li, X. et al. A non-invasive model for Predicting Liver inflammation in Chronic Hepatitis B patients with normal serum alanine aminotransferase levels. Front. Med. (Lausanne). 8, 688091 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"Suppl 1","key":"87756_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/jvh.13163","volume":"26","author":"Y Xie","year":"2019","unstructured":"Xie, Y. et al. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J. Viral Hepat. 26 (Suppl 1), 42\u201349 (2019).","journal-title":"J. Viral Hepat."},{"key":"87756_CR22","doi-asserted-by":"publisher","first-page":"661725","DOI":"10.3389\/fmed.2021.661725","volume":"8","author":"S Chen","year":"2021","unstructured":"Chen, S. & Huang, H. Clinical non-invasive model to Predict Liver inflammation in Chronic Hepatitis B with Alanine Aminotransferase\u2009\u2264\u20092 Upper Limit of Normal. Front. Med. (Lausanne). 8, 661725 (2021).","journal-title":"Front. Med. (Lausanne)"},{"issue":"6","key":"87756_CR23","doi-asserted-by":"publisher","first-page":"101563","DOI":"10.1016\/j.clinre.2020.10.008","volume":"45","author":"Z Chi","year":"2021","unstructured":"Chi, Z. et al. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin. Res. Hepatol. Gastroenterol. 45 (6), 101563 (2021).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"87756_CR24","doi-asserted-by":"publisher","first-page":"175628482110106","DOI":"10.1177\/17562848211010675","volume":"14","author":"DW Zeng","year":"2021","unstructured":"Zeng, D. W. et al. A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study. Th. Adv. Gastroenterol. 14, 17562848211010675 (2021).","journal-title":"Th. Adv. Gastroenterol."},{"issue":"9663","key":"87756_CR25","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","volume":"373","author":"YF Liaw","year":"2009","unstructured":"Liaw, Y. F. & Chu, C. M. Hepatitis B virus infection. Lancet 373 (9663), 582\u2013592 (2009).","journal-title":"Lancet"},{"issue":"2","key":"87756_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12072-008-9065-2","volume":"2","author":"SK Sarin","year":"2008","unstructured":"Sarin, S. K. & Kumar, M. Should chronic HBV infected patients with normal ALT treated: debate. Hepatol. Int. 2 (2), 179\u2013184 (2008).","journal-title":"Hepatol. Int."},{"issue":"5","key":"87756_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/gutjnl-2017-314904","volume":"67","author":"GA Kim","year":"2018","unstructured":"Kim, G. A. et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut 67 (5), 945\u2013952 (2018).","journal-title":"Gut"},{"issue":"Suppl 1","key":"87756_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2893.2010.01270.x","volume":"17","author":"HL Gui","year":"2010","unstructured":"Gui, H. L. et al. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J. Viral Hepat. 17 (Suppl 1), 44\u201350 (2010).","journal-title":"J. Viral Hepat."},{"issue":"3","key":"87756_CR29","doi-asserted-by":"publisher","first-page":"E133","DOI":"10.1111\/hepr.12937","volume":"48","author":"J Li","year":"2018","unstructured":"Li, J. et al. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. Hepatol. Res. 48 (3), E133\u2013e145 (2018).","journal-title":"Hepatol. Res."},{"issue":"9","key":"87756_CR30","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1478-3231.2011.02570.x","volume":"31","author":"JY Cheong","year":"2011","unstructured":"Cheong, J. Y. et al. Serum markers for necroinflammatory activity in patients with chronic viral hepatitis and normal or mildly elevated aminotransferase levels. Liver Int. 31 (9), 1352\u20131358 (2011).","journal-title":"Liver Int."},{"key":"87756_CR31","doi-asserted-by":"publisher","first-page":"1137738","DOI":"10.3389\/fpubh.2023.1137738","volume":"11","author":"S Li","year":"2023","unstructured":"Li, S. et al. Identification of pseudo-immune tolerance for chronic hepatitis B patients: development and validation of a non-invasive prediction model. Front. Public. Health. 11, 1137738 (2023).","journal-title":"Front. Public. Health"},{"issue":"3","key":"87756_CR32","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1002\/hep.510290312","volume":"29","author":"SM Lin","year":"1999","unstructured":"Lin, S. M. et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29 (3), 971\u2013975 (1999).","journal-title":"Hepatology"},{"issue":"18","key":"87756_CR33","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.3748\/wjg.v11.i18.2841","volume":"11","author":"XM Li","year":"2005","unstructured":"Li, X. M. et al. Analyses of prognostic indices of chronic liver failure caused by Hepatitis virus. World J. Gastroenterol. 11 (18), 2841\u20132843 (2005).","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"87756_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcna.2013.09.005","volume":"98","author":"TA Woreta","year":"2014","unstructured":"Woreta, T. A. & Alqahtani, S. A. Evaluation of abnormal liver tests. Med. Clin. North. Am. 98 (1), 1\u201316 (2014).","journal-title":"Med. Clin. North. Am."},{"key":"87756_CR35","doi-asserted-by":"crossref","unstructured":"Wang, F. et al. Long-Term trends of Liver Cancer incidence and mortality in China 1990\u20132017: a joinpoint and age-period-cohort analysis. Int. J. Environ. Res. Public. Health, 16(16), 1\u201313 (2019).","DOI":"10.3390\/ijerph16162878"},{"key":"87756_CR36","doi-asserted-by":"crossref","unstructured":"Jeng, W. J. & Lok, A. S. Should treatment indications for chronic Hepatitis B be expanded? Clin Gastroenterol Hepatol, 19(10),  2006\u20132014. (2021).","DOI":"10.1016\/j.cgh.2020.04.091"},{"issue":"11","key":"87756_CR37","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/jmv.24879","volume":"89","author":"S Barut","year":"2017","unstructured":"Barut, S. et al. Predictors of histological indication for treatment in HBeAg negative chronic HBV infection. J. Med. Virol. 89 (11), 1952\u20131957 (2017).","journal-title":"J. Med. Virol."},{"key":"87756_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2016.09.007","volume":"52","author":"A Ormeci","year":"2016","unstructured":"Ormeci, A. et al. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. Int. J. Infect. Dis. 52, 68\u201373 (2016).","journal-title":"Int. J. Infect. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87756-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87756-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T23:19:06Z","timestamp":1737674346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87756-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87756"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87756-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"3031"}}